Immunome, Inc. (IMNM) 10-Year Financial Performance & Capital Metrics

IMNM • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsImmuno-Oncology

AboutImmunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.Show more

Revenue $9M -35.5%
EBITDA -$304M -179.1%
Net Income -$293M -174.3%
EPS (Diluted) -5.00 +7.1%
Gross Margin 100%
EBITDA Margin -3359.12% -332.8%
Operating Margin -3382.37% -332.9%
Net Margin -3240.38% -325.3%
ROE -194.63% -24.4%
ROIC -700.32% +17.0%
Debt/Equity 0.03 +93.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 94 (top 6%)

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Negative free cash flow
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-4.44%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM27.05%

EPS CAGR

10Y-

5Y-

3Y-

TTM83.76%

ROCE

10Y Avg-167.22%

5Y Avg-114.58%

3Y Avg-154.02%

Latest-195.62%

Peer Comparison

Immuno-Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
IMTXImmatics N.V.	1.26B	9.38	67	188.6%	-136.72%	-27.81%	0.03
CTMXCytomX Therapeutics, Inc.	692.99M	4.09	10.76	36.45%	24.66%	26.09%
IOVAIovance Biotherapeutics, Inc.	932.87M	2.35	-1.84	136.99%	-158.78%	-56.62%	0.08
REPLReplimune Group, Inc.	630.68M	8.04	-2.62			-117.82%	0.18
IMNMImmunome, Inc.	2.22B	20.14	-4.03	-35.5%	-23.01%	-84.4%	0.03
NKTRNektar Therapeutics	744.1M	36.58	-4.21	9.22%	-192.87%	-141.9%	1.69
IBRXImmunityBio, Inc.	2.78B	2.82	-4.55	22.71%	-422.28%
CRVSCorvus Pharmaceuticals, Inc.	485.43M	6.50	-6.37			-21.01%	0.03

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	14.02M	9.04M
Revenue Growth %	-	-	-	-	-	-	-0.36%
Cost of Goods Sold+	521K	615K	755K	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-
Gross Profit+	-521K	-615K	-755K	0	0	14.02M	9.04M
Gross Margin %	-	-	-	-	-	1%	1%
Gross Profit Growth %	-	-0.18%	-0.23%	1%	-	-	-0.36%
Operating Expenses+	7.74M	10.35M	11.51M	25.2M	36.9M	123.55M	314.84M
OpEx % of Revenue	-	-	-	-	-	8.81%	34.82%
Selling, General & Admin	866K	1.52M	4.78M	11.09M	13.63M	19.66M	32.95M
SG&A % of Revenue	-	-	-	-	-	1.4%	3.65%
Research & Development	6.88M	8.82M	6.73M	14.11M	23.27M	23.09M	129.54M
R&D % of Revenue	-	-	-	-	-	1.65%	14.33%
Other Operating Expenses	0	0	0	0	0	80.8M	152.34M
Operating Income+	-7.74M	-10.35M	-12.26M	-25.2M	-36.9M	-109.53M	-305.8M
Operating Margin %	-	-	-	-	-	-7.81%	-33.82%
Operating Income Growth %	-	-0.34%	-0.18%	-1.06%	-0.46%	-1.97%	-1.79%
EBITDA+	-7.22M	-9.73M	-11.51M	-24.45M	-36.27M	-108.8M	-303.7M
EBITDA Margin %	-	-	-	-	-	-7.76%	-33.59%
EBITDA Growth %	-	-0.35%	-0.18%	-1.12%	-0.48%	-2%	-1.79%
D&A (Non-Cash Add-back)	521K	615K	755K	755K	631K	728K	2.1M
EBIT	-7.7M	-10.34M	-17.8M	-25.2M	-36.9M	-28.73M	-153.46M
Net Interest Income+	-102K	-96K	-37K	0	0	2.72M	12.84M
Interest Income	39K	10K	1K	10K	5K	2.72M	12.84M
Interest Expense	141K	106K	38K	10K	5K	0	0
Other Income/Expense	-102K	-96K	-5.58M	493K	5K	2.72M	12.84M
Pretax Income+	-7.84M	-10.44M	-17.84M	-24.71M	-36.9M	-106.81M	-292.96M
Pretax Margin %	-	-	-	-	-	-7.62%	-32.4%
Income Tax+	39K	0	0	0	0	0	0
Effective Tax Rate %	1%	1.01%	1%	1%	1%	1%	1%
Net Income+	-7.84M	-10.55M	-17.84M	-24.71M	-36.9M	-106.81M	-292.96M
Net Margin %	-	-	-	-	-	-7.62%	-32.4%
Net Income Growth %	-	-0.34%	-0.69%	-0.39%	-0.49%	-1.89%	-1.74%
Net Income (Continuing)	-7.84M	-10.44M	-17.84M	-24.71M	-36.9M	-106.81M	-292.96M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	-7.18	-1.84	-1.69	-2.14	-3.09	-5.38	-5.00
EPS Growth %	-	0.74%	0.08%	-0.27%	-0.44%	-0.74%	0.07%
EPS (Basic)	-7.18	-1.84	-1.69	-2.14	-3.09	-5.38	-5.00
Diluted Shares Outstanding	1.09M	5.74M	10.11M	11.54M	12.13M	19.84M	58.64M
Basic Shares Outstanding	1.09M	5.74M	10.11M	11.54M	12.13M	19.84M	58.64M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.11M	3.12M	42.89M	56.64M	22.65M	144.7M	221.34M
Cash & Short-Term Investments	1.6M	2.54M	39.77M	49.23M	20.32M	138.14M	217.3M
Cash Only	1.6M	2.54M	39.77M	49.23M	20.32M	98.68M	143.35M
Short-Term Investments	0	0	0	0	0	39.46M	73.95M
Accounts Receivable	0	0	850K	4.31M	847K	289K	0
Days Sales Outstanding	-	-	-	-	-	7.53	-
Inventory	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-
Other Current Assets	509K	0	0	0	0	4.99M	4.04M
Total Non-Current Assets+	2.34M	1.94M	1.63M	1.29M	1.4M	3.84M	18.9M
Property, Plant & Equipment	2.08M	1.7M	1.53M	855K	965K	3.64M	14.39M
Fixed Asset Turnover	-	-	-	-	-	3.85x	0.63x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0
Long-Term Investments	100K	0	100K	100K	0	100K	0
Other Non-Current Assets	155K	238K	0	332K	432K	100K	4.51M
Total Assets+	4.45M	5.06M	44.52M	57.92M	24.05M	148.54M	240.24M
Asset Turnover	-	-	-	-	-	0.09x	0.04x
Asset Growth %	-	0.14%	7.8%	0.3%	-0.58%	5.18%	0.62%
Total Current Liabilities+	1.56M	1.67M	3.04M	9.73M	7.33M	21.83M	54.31M
Accounts Payable	473K	548K	1.19M	3.08M	2.4M	3.31M	14.19M
Days Payables Outstanding	331.37	325.24	573.85	-	-	-	-
Short-Term Debt	225K	212K	479K	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	1000K	1000K
Other Current Liabilities	83K	426K	527K	2.02M	1.96M	4.98M	8M
Current Ratio	1.35x	1.88x	14.12x	5.82x	3.09x	6.63x	4.08x
Quick Ratio	1.35x	1.88x	14.12x	5.82x	3.09x	6.63x	4.08x
Cash Conversion Cycle	-	-	-	-	-	-	-
Total Non-Current Liabilities+	28.09M	39.02M	142K	12K	62K	6.83M	4.77M
Long-Term Debt	325K	113K	134K	0	0	0	0
Capital Lease Obligations	239K	0	0	0	62K	1.34M	4.77M
Deferred Tax Liabilities	0	0	0	0	0	-5.49M	0
Other Non-Current Liabilities	27.53M	38.91M	8K	12K	0	5.49M	0
Total Liabilities	29.65M	40.69M	3.18M	9.74M	7.39M	28.66M	59.08M
Total Debt+	1.18M	564K	613K	317K	291K	1.65M	4.83M
Net Debt	-426K	-1.98M	-39.15M	-48.91M	-20.03M	-97.03M	-138.52M
Debt / Equity	-	-	0.01x	0.01x	0.02x	0.01x	0.03x
Debt / EBITDA	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-
Interest Coverage	-54.91x	-97.62x	-322.66x	-2520.40x	-7380.20x	-	-
Total Equity+	-25.2M	-35.63M	41.34M	48.19M	16.65M	119.88M	181.16M
Equity Growth %	-	-0.41%	2.16%	0.17%	-0.65%	6.2%	0.51%
Book Value per Share	-23.07	-6.20	4.09	4.18	1.37	6.04	3.09
Total Shareholders' Equity	-25.2M	-35.63M	41.34M	48.19M	16.65M	119.88M	181.16M
Common Stock	1K	0	1K	1K	1K	4K	6K
Retained Earnings	-26.11M	-36.56M	-54.39M	-79.11M	-116M	-222.81M	-515.77M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-904K	0	-44.52M	-57.92M	0	22K	57K
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-7.41M	-9.6M	-12.13M	-18.23M	-28.69M	-7.57M	-110.79M
Operating CF Margin %	-	-	-	-	-	-0.54%	-12.25%
Operating CF Growth %	-	-0.3%	-0.26%	-0.5%	-0.57%	0.74%	-13.64%
Net Income	-7.84M	-10.44M	-17.84M	-24.71M	-36.9M	-106.81M	-292.96M
Depreciation & Amortization	521K	615K	755K	755K	631K	728K	2.1M
Stock-Based Compensation	11K	0	621K	3.45M	5.33M	6.22M	15.75M
Deferred Taxes	0	0	5.54M	-500K	-7.27M	0	0
Other Non-Cash Items	9K	17K	-2K	4K	7.27M	80.29M	149.44M
Working Capital Changes	-102K	212K	-1.21M	2.78M	2.24M	12M	14.87M
Change in Receivables	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0
Change in Payables	146K	75K	504K	1.78M	-677K	-608K	9.53M
Cash from Investing+	-228K	-233K	-586K	-79K	-248K	-30.48M	-85.06M
Capital Expenditures	-228K	-233K	-586K	-79K	-248K	-831K	-7.17M
CapEx % of Revenue	-	-	-	-	-	0.06%	0.79%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-46.34M
Cash from Financing+	-551K	10.77M	49.94M	27.77M	32K	116.41M	240.53M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	0	-6M	656K	0	116.37M	-9.47M
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-7.63M	-9.83M	-12.72M	-18.3M	-28.94M	-8.4M	-164.3M
FCF Margin %	-	-	-	-	-	-0.6%	-18.17%
FCF Growth %	-	-0.29%	-0.29%	-0.44%	-0.58%	0.71%	-18.56%
FCF per Share	-6.99	-1.71	-1.26	-1.59	-2.39	-0.42	-2.80
FCF Conversion (FCF/Net Income)	0.94x	0.91x	0.68x	0.74x	0.78x	0.07x	0.38x
Interest Paid	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-624.22%	-55.2%	-113.81%	-156.45%	-194.63%
Return on Invested Capital (ROIC)	-	-	-	-2580.61%	-	-843.66%	-700.32%
Gross Margin	-	-	-	-	-	100%	100%
Net Margin	-	-	-	-	-	-761.92%	-3240.38%
Debt / Equity	-	-	0.01x	0.01x	0.02x	0.01x	0.03x
Interest Coverage	-54.91x	-97.62x	-322.66x	-2520.40x	-7380.20x	-	-
FCF Conversion	0.94x	0.91x	0.68x	0.74x	0.78x	0.07x	0.38x
Revenue Growth	-	-	-	-	-	-	-35.5%

Frequently Asked Questions

Growth & Financials

Immunome, Inc. (IMNM) reported $9.7M in revenue for fiscal year 2024.

Immunome, Inc. (IMNM) saw revenue decline by 35.5% over the past year.

Immunome, Inc. (IMNM) reported a net loss of $222.7M for fiscal year 2024.

Dividend & Returns

Immunome, Inc. (IMNM) has a return on equity (ROE) of -194.6%. Negative ROE indicates the company is unprofitable.

Immunome, Inc. (IMNM) had negative free cash flow of $192.1M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener